Eli Lilly and Company (NYSE:LLY) Receives $311.00 Consensus Target Price from Brokerages

Shares of Eli Lilly and Company (NYSE:LLYGet Rating) have been assigned an average recommendation of “Moderate Buy” from the nineteen analysts that are covering the company, Marketbeat reports. Two equities research analysts have rated the stock with a hold recommendation and twelve have assigned a buy recommendation to the company. The average twelve-month target price among brokerages that have updated their coverage on the stock in the last year is $311.00.

A number of equities analysts recently issued reports on LLY shares. The Goldman Sachs Group raised their price objective on shares of Eli Lilly and from $234.00 to $264.00 and gave the stock a “neutral” rating in a report on Tuesday, April 12th. Bank of America raised their target price on shares of Eli Lilly and from $300.00 to $315.00 in a research note on Thursday, March 17th. JPMorgan Chase & Co. raised their target price on shares of Eli Lilly and from $340.00 to $355.00 in a research note on Wednesday, June 1st. Mizuho raised their target price on shares of Eli Lilly and from $315.00 to $356.00 in a research note on Monday, May 2nd. Finally, SVB Leerink assumed coverage on shares of Eli Lilly and in a research note on Monday, May 23rd. They set an “outperform” rating and a $341.00 target price on the stock.

Shares of NYSE LLY opened at $312.72 on Tuesday. The firm’s 50-day moving average price is $297.70 and its 200-day moving average price is $275.42. The company has a quick ratio of 0.98, a current ratio of 1.27 and a debt-to-equity ratio of 1.60. The company has a market cap of $297.13 billion, a PE ratio of 46.33, a PEG ratio of 2.06 and a beta of 0.40. Eli Lilly and has a 52-week low of $220.20 and a 52-week high of $324.08.

Eli Lilly and (NYSE:LLYGet Rating) last posted its quarterly earnings data on Thursday, April 28th. The company reported $2.62 earnings per share (EPS) for the quarter, topping analysts’ consensus estimates of $2.32 by $0.30. The company had revenue of $7.81 billion for the quarter, compared to the consensus estimate of $7.29 billion. Eli Lilly and had a net margin of 20.90% and a return on equity of 97.58%. The firm’s revenue was up 14.8% compared to the same quarter last year. During the same quarter last year, the firm posted $1.87 earnings per share. As a group, equities research analysts anticipate that Eli Lilly and will post 8.27 EPS for the current fiscal year.

The business also recently disclosed a quarterly dividend, which was paid on Friday, June 10th. Stockholders of record on Monday, May 16th were given a dividend of $0.98 per share. This represents a $3.92 annualized dividend and a dividend yield of 1.25%. The ex-dividend date was Friday, May 13th. Eli Lilly and’s payout ratio is currently 58.07%.

In related news, CAO Donald A. Zakrowski sold 1,000 shares of the firm’s stock in a transaction on Wednesday, June 1st. The shares were sold at an average price of $313.44, for a total value of $313,440.00. Following the completion of the transaction, the chief accounting officer now directly owns 6,274 shares of the company’s stock, valued at $1,966,522.56. The transaction was disclosed in a legal filing with the SEC, which is available at the SEC website. Also, major shareholder Lilly Endowment Inc sold 200,000 shares of the firm’s stock in a transaction on Friday, May 27th. The shares were sold at an average price of $318.98, for a total transaction of $63,796,000.00. Following the completion of the transaction, the insider now directly owns 104,833,810 shares of the company’s stock, valued at $33,439,888,713.80. The disclosure for this sale can be found here. Over the last three months, insiders sold 1,058,630 shares of company stock valued at $323,676,345. 0.12% of the stock is currently owned by insiders.

A number of hedge funds and other institutional investors have recently bought and sold shares of the business. Vanguard Group Inc. boosted its stake in Eli Lilly and by 1.8% during the first quarter. Vanguard Group Inc. now owns 70,481,178 shares of the company’s stock worth $20,183,695,000 after buying an additional 1,219,424 shares during the period. State Street Corp boosted its stake in Eli Lilly and by 2.5% during the fourth quarter. State Street Corp now owns 33,929,864 shares of the company’s stock worth $9,372,107,000 after buying an additional 813,983 shares during the period. Capital World Investors boosted its stake in Eli Lilly and by 17.0% during the first quarter. Capital World Investors now owns 22,358,444 shares of the company’s stock worth $6,402,838,000 after buying an additional 3,242,548 shares during the period. Geode Capital Management LLC boosted its stake in shares of Eli Lilly and by 2.9% during the fourth quarter. Geode Capital Management LLC now owns 14,731,168 shares of the company’s stock valued at $4,059,130,000 after purchasing an additional 409,009 shares during the period. Finally, Capital International Investors boosted its stake in shares of Eli Lilly and by 30.5% during the first quarter. Capital International Investors now owns 8,839,241 shares of the company’s stock valued at $2,532,024,000 after purchasing an additional 2,063,557 shares during the period. 82.75% of the stock is owned by institutional investors.

About Eli Lilly and (Get Rating)

Eli Lilly and Company discovers, develops, and markets human pharmaceuticals worldwide. It offers Basaglar, Humalog, Humalog Mix 75/25, Humalog U-100, Humalog U-200, Humalog Mix 50/50, insulin lispro, insulin lispro protamine, insulin lispro mix 75/25, Humulin, Humulin 70/30, Humulin N, Humulin R, and Humulin U-500 for diabetes; and Jardiance, Trajenta, and Trulicity for type 2 diabetes.

Featured Stories

Analyst Recommendations for Eli Lilly and (NYSE:LLY)

Receive News & Ratings for Eli Lilly and Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Eli Lilly and and related companies with MarketBeat.com's FREE daily email newsletter.